Reduced chemotherapy duration: A good idea?

Joleen M Hubbard, Axel F Grothey

Research output: Contribution to journalArticle

Abstract

Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)241-245
Number of pages5
JournalCurrent Colorectal Cancer Reports
Volume7
Issue number3
DOIs
StatePublished - 2011

Fingerprint

oxaliplatin
Drug Therapy
Colonic Neoplasms
Peripheral Nervous System Diseases
Adjuvant Chemotherapy
Standard of Care
Therapeutics
History
Research Personnel
Clinical Trials

Keywords

  • 5-fluorouracil
  • Adjuvant therapy
  • Chemotherapy-induced sensory neuropathy
  • Colon cancer
  • Oxaliplatin
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Reduced chemotherapy duration : A good idea? / Hubbard, Joleen M; Grothey, Axel F.

In: Current Colorectal Cancer Reports, Vol. 7, No. 3, 2011, p. 241-245.

Research output: Contribution to journalArticle

Hubbard, Joleen M ; Grothey, Axel F. / Reduced chemotherapy duration : A good idea?. In: Current Colorectal Cancer Reports. 2011 ; Vol. 7, No. 3. pp. 241-245.
@article{13b76b11467142ea869515f91b6c9a2c,
title = "Reduced chemotherapy duration: A good idea?",
abstract = "Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.",
keywords = "5-fluorouracil, Adjuvant therapy, Chemotherapy-induced sensory neuropathy, Colon cancer, Oxaliplatin, Peripheral neuropathy",
author = "Hubbard, {Joleen M} and Grothey, {Axel F}",
year = "2011",
doi = "10.1007/s11888-011-0100-7",
language = "English (US)",
volume = "7",
pages = "241--245",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Reduced chemotherapy duration

T2 - A good idea?

AU - Hubbard, Joleen M

AU - Grothey, Axel F

PY - 2011

Y1 - 2011

N2 - Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.

AB - Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.

KW - 5-fluorouracil

KW - Adjuvant therapy

KW - Chemotherapy-induced sensory neuropathy

KW - Colon cancer

KW - Oxaliplatin

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84856222488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856222488&partnerID=8YFLogxK

U2 - 10.1007/s11888-011-0100-7

DO - 10.1007/s11888-011-0100-7

M3 - Article

AN - SCOPUS:84856222488

VL - 7

SP - 241

EP - 245

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -